en
Scientific article
Open access
English

Clinical considerations of isavuconazole administration in high-risk hematological patients: a single-center 5-year experience

Published inMycopathologia, vol. 186, p. 775-788
Publication date2021
First online date2021-08-25
Abstract

Background: There are limited real-life data on isavuconazole prophylaxis and treatment of invasive mold infections (IMI) in hematological patients and allogeneic hematopoietic cell transplant (HCT) recipients. Objectives: Primary objective was to describe the indications of real-life isavuconazole administration at a university hospital. Secondary objectives included the description of liver function tests and QTc interval between baseline and end of treatment (EOT), clinical outcomes and breakthrough IMI by the EOT. Patients/methods: This was a 5-year single-center retrospective study of all adult patients with acute myeloid leukemia and/or allogeneic HCT recipients who received isavuconazole as prophylaxis and/or treatment between June 1, 2016, and July 31, 2020. Results: Among 30 identified patients, the indications for isavuconazole administration were adverse events associated with prior antifungal treatment (N: 18, 60%: hepatotoxicity, renal insufficiency, long QTc interval, neurotoxicity, and potential drug-drug interactions in 6, 4, 3, 1 and 4 patients, respectively), clinical efficacy (N: 5, 16.6%), and other reasons (N: 10, 33.3%; 5/10 patients treated with isavuconazole to facilitate hospital discharge with orally administered appropriate treatment). Alanine aminotransferase significantly decreased from baseline (mean: 129 IU/L, range: 73, 202) to a mean of 48 IU/L (range: 20, 80) by day 14 (P-value: 0.02), 23.5 IU/L (range: 20, 27) by day 28 (P-value: 0.03) and 16.5 IU/L (range: 16, 17) by day 42 (P-value: 0.009). The QTc interval decreased from baseline (mean: 456.8 ms, range: 390, 533) to EOT (mean: 433.8 ms, range: 400, 472; P-value: 0.03). The mean isavuconazole plasma concentration was 2.9 mg/L (range: 0.9, 6.7). There was no breakthrough IMI observed. Conclusion: Isavuconazole is a safe and reliable antifungal agent in complex hematological patients, with relatively low hepatotoxicity and QTc interval shortening properties.

eng
Keywords
  • Acute myelogenous leukemia
  • Allogeneic hematopoietic cell transplant recipients
  • Invasive mold infections
  • Isavuconazole
  • Prophylaxis
  • Treatment
Citation (ISO format)
KRONIG, Ilona et al. Clinical considerations of isavuconazole administration in high-risk hematological patients: a single-center 5-year experience. In: Mycopathologia, 2021, vol. 186, p. 775–788. doi: 10.1007/s11046-021-00583-9
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal0301-486X
156views
48downloads

Technical informations

Creation10/21/2021 8:14:00 AM
First validation10/21/2021 8:14:00 AM
Update time03/16/2023 6:27:09 AM
Status update03/16/2023 6:27:08 AM
Last indexation02/12/2024 12:22:22 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack